FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Trial details
- Registry ID
- NCT06788990
- Drugs studied
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
TrialRedline tracks 1 clinical trial sponsored by Bicara Therapeutics: 1 Phase 2 / 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCNCT06788990 | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) | Recruiting | 2028-04Estimated |
Names as written in the registry records.